Select therapeutic use:
Indications for ISENTRESS ORAL SUSPENSION:
HIV-1 infection, in combination with other antiretrovirals.
Use film-coated tabs.
<4 weeks: not established. Mix susp packet contents with 5mL of water; administer using oral syringe within 30mins. ≥4 weeks (3–<4kg): 20mg (1mL) twice daily; (4–<6kg): 30mg (1.5mL) twice daily; (6–<8kg): 40mg (2mL) twice daily; (8–<11kg): 60mg (3mL) twice daily; (11–<14kg): 80mg (4mL) twice daily or 75mg chew tabs twice daily; (14–<20kg): 100mg (5mL or chew tabs) twice daily; (20–<25kg): 150mg chew tabs twice daily. Oral susp max dose: 100mg (5mL) twice daily. See full labeling.
Chew tabs or oral susp are not interchangeable with the film-coated tabs. Monitor liver aminotransferases, myopathy, and rhabdomyolysis. Discontinue if signs/symptoms of severe skin or hypersensitivity reactions develop. Hepatic impairment: Isentress HD not recommended. Pregnancy. Nursing mothers: not recommended.
May be antagonized by UGT1A1 inducers (eg, rifampin; see Adult) and potentiated by UGT1A1 inhibitors. Concomitant aluminum and/or magnesium-containing antacids, other strong enzyme inducers (eg, carbamazepine, phenobarbital, phenytoin): not recommended. Caution with concomitant drugs known to cause myopathy or rhabdomyolysis (eg, statins). Isentress HD: concomitant calcium carbonate antacid, rifampin, tipranavir/ritonavir, etravirine: not recommended.
HIV-1 integrase strand transfer inhibitor (INSTI).
Insomnia, headache, dizziness, nausea, fatigue, creatinine kinase elevations, myopathy, rhabdomyolysis; severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), hypersensitivity, immune reconstitution syndrome.
Note: Register pregnant patients exposed to raltegravir by calling (800) 258-4263.
Chew tabs, film-coated tabs—60; Susp (pkts)—1, 60 (w. syringes, mixing cups)